2019
Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials
Yu J, Singh C, Bindra R, Contessa J, Husain Z, Hansen J, Park H, Roberts K, Bond J, Tien C, Guo F, Colaco R, Housri N, Magnuson W, Mahajan A, Omay S, Chiang V. Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials. Journal Of Radiation Oncology 2019, 8: 39-46. DOI: 10.1007/s13566-018-0370-7.Peer-Reviewed Original ResearchYale-New Haven HospitalPhase II studyBrain metastasesClinical trialsII studyKnife radiosurgeryLocal controlPre-defined primary endpointWhole-brain radiation treatmentFuture prospective clinical trialsEvaluable brain metastasesSymptomatic radiation necrosisMedian patient ageLocal control ratePhase 2 studyGood local controlProspective clinical trialsNumber of metastasesLarge clinical trialsProportional hazards regressionFuture clinical trialsGamma knife radiosurgeryImportant clinical variablesStandard clinical practiceNew Haven Hospital
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancer
1997
Treatment of recurrent pelvic and selected primary gynecologic malignancies with 241Am
Chung J, Roberts K, Peschel R, Nath R, Pourang R, Kacinski B, Wilson L. Treatment of recurrent pelvic and selected primary gynecologic malignancies with 241Am. International Journal Of Cancer 1997, 5: 227-234. PMID: 9372545, DOI: 10.1002/(sici)1520-6823(1997)5:5<227::aid-roi3>3.0.co;2-#.Peer-Reviewed Original ResearchConceptsRecurrent pelvic malignanciesPrimary gynecologic malignanciesPrimary radiotherapySurgical salvageMicroscopic diseasePelvic malignanciesPostoperative radiotherapyGynecologic malignanciesUltimate local control rateExternal beam radiation therapyGross primary tumorMedian patient ageLocal control rateTreatment of recurrentBeam radiation therapyMicroscopic residuumTreatment intentPatient ageSurgical resectionCurative therapyGynecologic tumorsGynecologic cancerControl ratePrimary tumorRadiation therapy